Tags

Type your tag names separated by a space and hit enter

Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.
J Clin Psychiatry 2009; 70(10):1365-71JC

Abstract

OBJECTIVE

To evaluate the effects of desvenlafaxine therapy on functioning and well-being in major depressive disorder (MDD).

METHOD

Total and individual item Sheehan Disability Scale (SDS) and 5-item World Health Organization Well-Being Index (WHO-5) scores from 8 double-blind, placebo-controlled, 8-week desvenlafaxine clinical trials were pooled. Scores on the 17-item Hamilton Depression Rating Scale (HDRS(17)) work/activities and Montgomery-Asberg Depression Rating Scale (MADRS) lassitude items were pooled from 9 studies. Outpatients with DSM-IV MDD were randomly assigned to fixed (5 studies; 50, 100, 200, or 400 mg/d; n = 1,342) or flexible (4 studies, 100-400 mg/d; n = 463) doses of desvenlafaxine or placebo (n = 1,108). Data from each patient's final evaluation were analyzed for the total population and for individual dose groups from the fixed-dose studies and were compared between groups using analysis of covariance.

RESULTS

Compared with placebo, desvenlafaxine therapy resulted in significantly greater improvements in SDS total score (-2.0) and individual items regarding work (-0.6), social life/leisure activities (-0.8), and family life/home responsibilities (-0.7; P < .001 for all comparisons), as well as WHO-5 total score (1.7) and individual items (good spirits [0.4], calm/relaxed [0.4], active/vigorous [0.3], fresh/rested [0.3], and interest [0.3]; P < .001 for all comparisons). Desvenlafaxine treatment resulted in significant improvements on the HDRS(17) work/activities (-0.2; P < .001) and MADRS lassitude (-0.3; P < .001) items compared with placebo. Significant differences were observed for the individual fixed-dose groups on all outcomes (P < .05); there was no evidence of a dose-response relationship.

CONCLUSIONS

Desvenlafaxine therapy resulted in significant improvements in the functioning and well-being among MDD patients.

Authors+Show Affiliations

Department of Psychiatry and Behavioural Neurosciences, Mood Disorders Division, McMaster University, Hamilton, Ontario, L8P 3B6, Canada. csoares@mcmaster.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19906341

Citation

Soares, Claudio N., et al. "Assessing the Efficacy of Desvenlafaxine for Improving Functioning and Well-being Outcome Measures in Patients With Major Depressive Disorder: a Pooled Analysis of 9 Double-blind, Placebo-controlled, 8-week Clinical Trials." The Journal of Clinical Psychiatry, vol. 70, no. 10, 2009, pp. 1365-71.
Soares CN, Kornstein SG, Thase ME, et al. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. J Clin Psychiatry. 2009;70(10):1365-71.
Soares, C. N., Kornstein, S. G., Thase, M. E., Jiang, Q., & Guico-Pabia, C. J. (2009). Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. The Journal of Clinical Psychiatry, 70(10), pp. 1365-71. doi:10.4088/JCP.09m05133blu.
Soares CN, et al. Assessing the Efficacy of Desvenlafaxine for Improving Functioning and Well-being Outcome Measures in Patients With Major Depressive Disorder: a Pooled Analysis of 9 Double-blind, Placebo-controlled, 8-week Clinical Trials. J Clin Psychiatry. 2009;70(10):1365-71. PubMed PMID: 19906341.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. AU - Soares,Claudio N, AU - Kornstein,Susan G, AU - Thase,Michael E, AU - Jiang,Qin, AU - Guico-Pabia,Christine J, PY - 2009/02/13/received PY - 2009/07/10/accepted PY - 2009/11/13/entrez PY - 2009/11/13/pubmed PY - 2009/12/16/medline SP - 1365 EP - 71 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 70 IS - 10 N2 - OBJECTIVE: To evaluate the effects of desvenlafaxine therapy on functioning and well-being in major depressive disorder (MDD). METHOD: Total and individual item Sheehan Disability Scale (SDS) and 5-item World Health Organization Well-Being Index (WHO-5) scores from 8 double-blind, placebo-controlled, 8-week desvenlafaxine clinical trials were pooled. Scores on the 17-item Hamilton Depression Rating Scale (HDRS(17)) work/activities and Montgomery-Asberg Depression Rating Scale (MADRS) lassitude items were pooled from 9 studies. Outpatients with DSM-IV MDD were randomly assigned to fixed (5 studies; 50, 100, 200, or 400 mg/d; n = 1,342) or flexible (4 studies, 100-400 mg/d; n = 463) doses of desvenlafaxine or placebo (n = 1,108). Data from each patient's final evaluation were analyzed for the total population and for individual dose groups from the fixed-dose studies and were compared between groups using analysis of covariance. RESULTS: Compared with placebo, desvenlafaxine therapy resulted in significantly greater improvements in SDS total score (-2.0) and individual items regarding work (-0.6), social life/leisure activities (-0.8), and family life/home responsibilities (-0.7; P < .001 for all comparisons), as well as WHO-5 total score (1.7) and individual items (good spirits [0.4], calm/relaxed [0.4], active/vigorous [0.3], fresh/rested [0.3], and interest [0.3]; P < .001 for all comparisons). Desvenlafaxine treatment resulted in significant improvements on the HDRS(17) work/activities (-0.2; P < .001) and MADRS lassitude (-0.3; P < .001) items compared with placebo. Significant differences were observed for the individual fixed-dose groups on all outcomes (P < .05); there was no evidence of a dose-response relationship. CONCLUSIONS: Desvenlafaxine therapy resulted in significant improvements in the functioning and well-being among MDD patients. SN - 1555-2101 UR - https://www.unboundmedicine.com/medline/citation/19906341/Assessing_the_efficacy_of_desvenlafaxine_for_improving_functioning_and_well_being_outcome_measures_in_patients_with_major_depressive_disorder:_a_pooled_analysis_of_9_double_blind_placebo_controlled_8_week_clinical_trials_ L2 - http://www.psychiatrist.com/jcp/article/pages/2009/v70n10/v70n1004.aspx DB - PRIME DP - Unbound Medicine ER -